MYO7A_HUMAN,M1T,0.967,Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Loss of N-terminal acetylation at M1 (Pr = 0.24 | P = 5.7e-04); Altered Metal binding (Pr = 0.06 | P = 0.03), ELME000335,-
MYO7A_HUMAN,V2G,0.927,Gain of Intrinsic disorder (Pr = 0.43 | P = 5.4e-03); Loss of N-terminal acetylation at M1 (Pr = 0.23 | P = 6.7e-04); Altered Stability (Pr = 0.12 | P = 0.03); Altered Metal binding (Pr = 0.04 | P = 0.04), None,-
MYO7A_HUMAN,I3R,0.878,Gain of Intrinsic disorder (Pr = 0.46 | P = 3.4e-03); Altered Metal binding (Pr = 0.25 | P = 0.03); Loss of N-terminal acetylation at M1 (Pr = 0.20 | P = 8.1e-04); Altered Transmembrane protein (Pr = 0.11 | P = 0.04); Altered Stability (Pr = 0.11 | P = 0.04), None,-
MYO7A_HUMAN,L4S,0.847,Gain of Intrinsic disorder (Pr = 0.58 | P = 5.1e-04); Altered Metal binding (Pr = 0.29 | P = 0.02); Altered Stability (Pr = 0.24 | P = 8.6e-03); Gain of N-terminal acetylation at M1 (Pr = 0.19 | P = 6.6e-04), ELME000202|ELME000336,-
MYO7A_HUMAN,Q5G,0.882,Altered Metal binding (Pr = 0.27 | P = 0.02); Altered Stability (Pr = 0.20 | P = 0.01); Loss of N-terminal acetylation at M1 (Pr = 0.19 | P = 9.4e-04), None,-
MYO7A_HUMAN,Q5L,0.854,Loss of Intrinsic disorder (Pr = 0.51 | P = 5.9e-03); Altered Metal binding (Pr = 0.40 | P = 6.3e-03); Loss of N-terminal acetylation at M1 (Pr = 0.19 | P = 8.8e-04), None,-
MYO7A_HUMAN,V27M,0.356,-,-,-
MYO7A_HUMAN,V36I,0.034,-,-,-
MYO7A_HUMAN,Q37L,0.668,Altered Metal binding (Pr = 0.31 | P = 0.01); Altered Transmembrane protein (Pr = 0.31 | P = 1.1e-04); Loss of Relative solvent accessibility (Pr = 0.23 | P = 0.05), ELME000333,-
MYO7A_HUMAN,N44H,0.204,-,-,-
MYO7A_HUMAN,D91E,0.362,-,-,-
MYO7A_HUMAN,S112T,0.285,-,-,-
MYO7A_HUMAN,E117K,0.751,Altered Metal binding (Pr = 0.34 | P = 9.0e-03); Altered Transmembrane protein (Pr = 0.32 | P = 5.8e-05); Gain of Relative solvent accessibility (Pr = 0.28 | P = 0.01); Altered Ordered interface (Pr = 0.25 | P = 0.02); Gain of Acetylation at E117 (Pr = 0.25 | P = 0.01); Gain of Allosteric site at Y114 (Pr = 0.24 | P = 0.02), ELME000063|ELME000136|ELME000159|PS00005,-
MYO7A_HUMAN,I178V,0.264,-,-,-
MYO7A_HUMAN,N222S,0.566,Altered Ordered interface (Pr = 0.31 | P = 0.02); Altered Metal binding (Pr = 0.28 | P = 5.7e-03); Gain of Acetylation at K223 (Pr = 0.27 | P = 6.3e-03); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Gain of Allosteric site at I227 (Pr = 0.24 | P = 0.01); Altered DNA binding (Pr = 0.22 | P = 0.01); Gain of Methylation at K223 (Pr = 0.10 | P = 0.04), PS00005,-
MYO7A_HUMAN,K223T,0.703,Loss of Acetylation at K223 (Pr = 0.45 | P = 7.9e-04); Altered Metal binding (Pr = 0.29 | P = 4.3e-03); Altered Ordered interface (Pr = 0.29 | P = 0.02); Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Loss of Allosteric site at R224 (Pr = 0.26 | P = 0.01); Altered DNA binding (Pr = 0.21 | P = 0.02); Loss of Methylation at K223 (Pr = 0.10 | P = 0.04), ELME000100|ELME000108,-
MYO7A_HUMAN,K231R,0.340,-,-,-
MYO7A_HUMAN,E233Q,0.603,Altered DNA binding (Pr = 0.30 | P = 1.6e-03); Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Metal binding (Pr = 0.25 | P = 9.9e-03); Loss of Relative solvent accessibility (Pr = 0.23 | P = 0.05); Gain of Allosteric site at Y235 (Pr = 0.22 | P = 0.03); Loss of Acetylation at K231 (Pr = 0.19 | P = 0.05); Loss of Catalytic site at E238 (Pr = 0.08 | P = 0.05), ELME000002,-
MYO7A_HUMAN,A246C,0.845,Altered Metal binding (Pr = 0.36 | P = 0.01); Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Allosteric site at R250 (Pr = 0.28 | P = 3.6e-03); Altered DNA binding (Pr = 0.17 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q245 (Pr = 0.07 | P = 0.02), ELME000146|PS00007,-
MYO7A_HUMAN,E249L,0.945,Altered Metal binding (Pr = 0.28 | P = 5.3e-03); Altered Ordered interface (Pr = 0.27 | P = 0.05); Loss of Allosteric site at H253 (Pr = 0.27 | P = 8.6e-03); Loss of Pyrrolidone carboxylic acid at Q245 (Pr = 0.06 | P = 0.03), ELME000233|PS00007,-
MYO7A_HUMAN,Y252A,0.958,Loss of Allosteric site at Y256 (Pr = 0.29 | P = 5.9e-03); Altered Metal binding (Pr = 0.25 | P = 0.01); Altered Ordered interface (Pr = 0.25 | P = 0.03); Gain of Catalytic site at Y256 (Pr = 0.10 | P = 0.04), ELME000120|PS00007,-
MYO7A_HUMAN,F255L,0.889,Altered Metal binding (Pr = 0.27 | P = 7.1e-03); Gain of Allosteric site at Y256 (Pr = 0.27 | P = 4.6e-03); Loss of Catalytic site at Y256 (Pr = 0.09 | P = 0.04), ELME000020|ELME000120,-
MYO7A_HUMAN,S263N,0.137,-,-,-
MYO7A_HUMAN,E264K,0.167,-,-,-
MYO7A_HUMAN,K267R,0.205,-,-,-
MYO7A_HUMAN,Q274R,0.071,-,-,-
MYO7A_HUMAN,S276A,0.100,-,-,-
MYO7A_HUMAN,S276N,0.217,-,-,-
MYO7A_HUMAN,S319L,0.676,Altered Ordered interface (Pr = 0.30 | P = 0.03); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered Metal binding (Pr = 0.10 | P = 0.04), ELME000149|ELME000193|ELME000335,-
MYO7A_HUMAN,Q332N,0.392,-,-,-
MYO7A_HUMAN,A335D,0.557,Altered Metal binding (Pr = 0.31 | P = 4.1e-04); Altered Ordered interface (Pr = 0.28 | P = 0.04); Gain of Loop (Pr = 0.27 | P = 0.03); Gain of Allosteric site at N330 (Pr = 0.26 | P = 8.1e-03); Altered Transmembrane protein (Pr = 0.16 | P = 0.01); Loss of Catalytic site at N330 (Pr = 0.13 | P = 0.03), ELME000147,-
MYO7A_HUMAN,A343S,0.181,-,-,-
MYO7A_HUMAN,A355V,0.365,-,-,-
MYO7A_HUMAN,L358H,0.805,Altered Stability (Pr = 0.14 | P = 0.02), ELME000064|ELME000155|ELME000335|PS00006,-
MYO7A_HUMAN,P364S,0.138,-,-,-
MYO7A_HUMAN,R388K,0.157,-,-,-
MYO7A_HUMAN,I414V,0.572,Altered Disordered interface (Pr = 0.42 | P = 3.1e-03); Gain of Allosteric site at W409 (Pr = 0.30 | P = 2.1e-03); Altered DNA binding (Pr = 0.24 | P = 0.01); Loss of Relative solvent accessibility (Pr = 0.23 | P = 0.05), None,-
MYO7A_HUMAN,Y419H,0.346,-,-,-
MYO7A_HUMAN,D494E,0.336,-,-,-
MYO7A_HUMAN,K502R,0.486,-,-,-
MYO7A_HUMAN,H526R,0.330,-,-,-
MYO7A_HUMAN,K527W,0.886,, ELME000202,-
MYO7A_HUMAN,Q531K,0.471,-,-,-
MYO7A_HUMAN,H532F,0.665,Gain of Relative solvent accessibility (Pr = 0.28 | P = 0.01); Gain of Acetylation at K533 (Pr = 0.19 | P = 0.05), ELME000173|ELME000202,-
MYO7A_HUMAN,N535T,0.517,Altered Ordered interface (Pr = 0.24 | P = 0.04), None,-
MYO7A_HUMAN,A536P,0.315,-,-,-
MYO7A_HUMAN,N544A,0.437,-,-,-
MYO7A_HUMAN,H545Y,0.288,-,-,-
MYO7A_HUMAN,G550W,0.842,Altered Ordered interface (Pr = 0.30 | P = 0.03); Altered Metal binding (Pr = 0.25 | P = 0.01); Loss of Allosteric site at H553 (Pr = 0.21 | P = 0.03); Altered Transmembrane protein (Pr = 0.15 | P = 0.02), ELME000080|ELME000202,-
MYO7A_HUMAN,N552I,0.589,Altered Metal binding (Pr = 0.43 | P = 9.1e-04); Altered Ordered interface (Pr = 0.36 | P = 3.8e-03); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Loss of Allosteric site at H553 (Pr = 0.24 | P = 0.02); Altered Transmembrane protein (Pr = 0.15 | P = 0.01), None,-
MYO7A_HUMAN,H553P,0.958,Altered Metal binding (Pr = 0.90 | P = 1.6e-04); Altered Ordered interface (Pr = 0.32 | P = 1.0e-02); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Loss of Allosteric site at H553 (Pr = 0.24 | P = 0.02); Altered Transmembrane protein (Pr = 0.15 | P = 0.02), ELME000056,-
MYO7A_HUMAN,A601V,0.186,-,-,-
MYO7A_HUMAN,E602P,0.636,Loss of Loop (Pr = 0.31 | P = 4.8e-03); Gain of ADP-ribosylation at R604 (Pr = 0.25 | P = 9.2e-03), ELME000053|ELME000271,-
MYO7A_HUMAN,R606A,0.767,Loss of ADP-ribosylation at R606 (Pr = 0.21 | P = 0.04); Gain of Ubiquitylation at K605 (Pr = 0.18 | P = 0.02), ELME000053|ELME000061|ELME000100|ELME000108|ELME000136|ELME000159|ELME000173|ELME000278|PS00004,-
MYO7A_HUMAN,T609W,0.896,Loss of Phosphorylation at S607 (Pr = 0.52 | P = 3.6e-03); Loss of Intrinsic disorder (Pr = 0.43 | P = 0.02); Loss of ADP-ribosylation at R604 (Pr = 0.21 | P = 0.04); Loss of Ubiquitylation at K605 (Pr = 0.15 | P = 0.05), ELME000061|ELME000136|ELME000159|ELME000173|ELME000202,-
MYO7A_HUMAN,H650Y,0.362,-,-,-
MYO7A_HUMAN,G699D,0.189,-,-,-
MYO7A_HUMAN,R702Q,0.301,-,-,-
MYO7A_HUMAN,G703R,0.742,, ELME000012|ELME000062|ELME000102|ELME000108|ELME000336,-
MYO7A_HUMAN,C705R,0.955,, ELME000012|ELME000062|ELME000336,-
MYO7A_HUMAN,Q706E,0.403,-,-,-
MYO7A_HUMAN,H732E,0.905,Altered Metal binding (Pr = 0.33 | P = 2.7e-03); Gain of Strand (Pr = 0.26 | P = 0.05); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03), None,-
MYO7A_HUMAN,M734L,0.432,-,-,-
MYO7A_HUMAN,M734S,0.738,Gain of Relative solvent accessibility (Pr = 0.33 | P = 2.7e-03); Altered Metal binding (Pr = 0.26 | P = 9.8e-03); Altered Stability (Pr = 0.12 | P = 0.03); Altered Transmembrane protein (Pr = 0.09 | P = 0.05), ELME000064|ELME000335|PS00006,-
MYO7A_HUMAN,V738M,0.205,-,-,-
MYO7A_HUMAN,R740G,0.940,Altered Stability (Pr = 0.32 | P = 4.8e-03), None,-
MYO7A_HUMAN,T772M,0.361,-,-,-
MYO7A_HUMAN,H777Y,0.354,-,-,-
MYO7A_HUMAN,N782H,0.200,-,-,-
MYO7A_HUMAN,N782T,0.305,-,-,-
MYO7A_HUMAN,K785R,0.118,-,-,-
MYO7A_HUMAN,N786S,0.246,-,-,-
MYO7A_HUMAN,L789M,0.134,-,-,-
MYO7A_HUMAN,K805M,0.296,-,-,-
MYO7A_HUMAN,H807Q,0.248,-,-,-
MYO7A_HUMAN,R811H,0.098,-,-,-
MYO7A_HUMAN,Q815E,0.155,-,-,-
MYO7A_HUMAN,Q819K,0.146,-,-,-
MYO7A_HUMAN,Q819N,0.159,-,-,-
MYO7A_HUMAN,A826G,0.166,-,-,-
MYO7A_HUMAN,L841I,0.095,-,-,-
MYO7A_HUMAN,M850L,0.246,-,-,-
MYO7A_HUMAN,R906C,0.287,-,-,-
MYO7A_HUMAN,E927Q,0.190,-,-,-
MYO7A_HUMAN,R931K,0.131,-,-,-
MYO7A_HUMAN,G958D,0.413,-,-,-
MYO7A_HUMAN,Q959R,0.248,-,-,-
MYO7A_HUMAN,S965R,0.163,-,-,-
MYO7A_HUMAN,E976D,0.116,-,-,-
MYO7A_HUMAN,E991D,0.246,-,-,-
MYO7A_HUMAN,D992E,0.130,-,-,-
MYO7A_HUMAN,A1005G,0.320,-,-,-
MYO7A_HUMAN,I1043V,0.185,-,-,-
MYO7A_HUMAN,T1059M,0.190,-,-,-
MYO7A_HUMAN,T1082M,0.424,-,-,-
MYO7A_HUMAN,K1084R,0.336,-,-,-
MYO7A_HUMAN,P1099A,0.143,-,-,-
MYO7A_HUMAN,E1100D,0.115,-,-,-
MYO7A_HUMAN,Q1102L,0.235,-,-,-
MYO7A_HUMAN,Q1102P,0.430,-,-,-
